Leadership

Markus has served as CEO of Gubra since September 2025, leading the company’s growth ambition across Biotech, CRO and Ventures. He brings extensive international leadership experience across biotechnology and global healthcare. Before joining Gubra, Markus held several CEO and Managing Director roles within the Roivant Group, leading ventures in immuno-oncology, infectious diseases and metabolic diseases. He currently chairs the boards of Roivant Sciences and Genevant Sciences in Switzerland. Earlier in his career, he led the Cardio-Metabolic and Ophthalmology Business Franchises at Novartis Pharma, including the launch of Entresto.
Markus holds a Ph.D. from Harvard Medical School.

Kristian is Chief Financial Officer (CFO) at Gubra, having joined the company in 2022 from Ascelia Pharma (listed on Nasdaq Stockholm), where he served as CFO. He has 25 years of experience that also include finance roles at Novozymes, Ørsted, and Danske Bank. Kristian holds an M.Sc. in Finance from Lund University, Sweden.

Louise leads Gubra’s scientific strategy and discovery activities, bringing more than 15 years of experience in peptide drug discovery with a focus on obesity and metabolic diseases. Louise has played a central role in shaping Gubra’s pipeline and in applying machine learning to peptide discovery through the streaMLine™ platform. Louise holds an M.Sc. in Pharmacy and a Ph.D. in Endocrinology, Diabetes and Metabolism from the University of Copenhagen.

Thomas leads Gubra’s preclinical and clinical development strategy, bringing more than 20 years of experience in translational medicine and clinical development across therapeutic areas and modalities. He previously served as Chief Medical Officer at Ethris and held senior roles at Novartis and Bristol Myers Squibb.

Thomas holds an M.D. from Humboldt University of Berlin, Germany and completed a postdoctoral fellowship in vascular biology at the NIH’s National Heart, Lung, and Blood Institute, Bethesda, USA.

Zoë leads Gubra Ventures and brings more than 25 years of experience as a senior executive and board director across global pharma, venture-backed biotech and company creation. Before joining Gubra, she served as Chief Scientific and Development Officer at Molecule to Medicine, a global biotech venture builder. She previously held Chief Scientific Officer roles at Affivant (a Roivant company) and iOnctura, and senior R&D positions at UCB, Merck Serono and NovImmune. Zoë holds a Ph.D. in Pharmacology from King’s College London.

Trine leads Gubra’s global preclinical contract research organization. She has held senior leadership roles at Gubra since 2017, including Chief Business Officer, where she oversaw commercial strategy, sales and marketing and led the opening of Gubra’s first U.S. office in Boston. Trine holds an Executive MBA from AVT Business School, Denmark.

Grigo leads Gubra’s Digital, Data & IT organisation and is a member of the Executive Leadership Team, having joined in February 2026. He brings nearly two decades of experience leading global technology organisations and driving digital transformation, with a focus on data, AI and engineering.

Previously, he served as Senior Director in Digital, Data & IT for Research & Early Development at Novo Nordisk, where he led teams across Architecture, Data & Engineering, including architecture work related to the Gefion AI supercomputer. Earlier, he held architecture & technology leadership roles at A.P. Møller–Maersk and Ørsted, following software engineering roles at Wipro and Tata Consultancy Services in India. Grigo holds PGMS in Geoinformatics and Bachelor of Computer Application.

Lena leads Gubra’s legal, compliance and corporate governance strategy across the Biotech, CRO and Ventures business units, acting as Chief Legal Officer and strategic partner to the CEO, the Board and the Executive Leadership Team. She brings more than 25 years of post-qualification experience, including more than 20 years in pharma, medtech and biotech across Denmark, the UK, Switzerland, France and Australia. She previously served as Group General Counsel at Telix Pharmaceuticals and held global and regional legal leadership roles at Gilead Sciences, Novartis and Bristol Myers Squibb. Earlier in her career, she worked across the IT, telecommunications, media and energy industries in Australia and the UK. Lena holds a Bachelor of Laws (LL.B.) from Flinders University and is admitted to the bar on three continents, in Australia, the UK and New York.